Related Experiment Video
Updated: Jul 5, 2026
05:44
Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
Published on: June 10, 2025
[Fluindione-induced acute generalised exanthematous pustulosis confirmed by patch testing]
M Chtioui1, F Cousin-Testard, U Zimmermann
1Service de dermatologie, hôpital Ambroise-Paré, Assistance publique-Hôpitaux de Paris, 9, avenue Charles-de-Gaulle, 92100 Boulogne-Billancourt, France.
Annales De Dermatologie Et De Venereologie
|April 19, 2008
Summary
Fluindione, a widely used anticoagulant, can cause acute generalized exanthematous pustulosis. Patch testing confirmed fluindione as the cause in a patient who recovered after drug withdrawal.
Area of Science:
- Dermatology
- Pharmacology
Background:
- Fluindione is a vitamin K antagonist oral anticoagulant widely prescribed in France.
- Cutaneous drug reactions to fluindione are rarely reported.
Observation:
- A 70-year-old woman developed a diffuse erythematous and pustular rash 48 hours after starting fluindione for cardiac arrhythmia.
- The rash resolved within eight days of discontinuing fluindione.
- Subsequent patch testing was positive for fluindione.
Findings:
- The patient's presentation and recovery were consistent with fluindione-induced acute generalized exanthematous pustulosis (AGEP).
- Positive patch tests strongly indicated fluindione as the causative agent.
- Warfarin was tolerated without adverse skin reactions.
Implications:
- This case highlights fluindione as a potential cause of AGEP.
- Skin patch-testing is a valuable diagnostic tool for identifying drug-induced cutaneous reactions.
- Clinicians should consider fluindione when evaluating patients with new-onset rash during anticoagulant therapy.